Home | Sitemap | Submit Content | Contact Us   
imageHome : Latest News : Data from Combination of REVLIMID® and Rituxan® in Untreated Indolent B-Cell Non-Hodgkin's ... - Yahoo Finance

Data from Combination of REVLIMID® and Rituxan® in Untreated Indolent B-Cell Non-Hodgkin's ... - Yahoo Finance

  • email Email to a friend
  • print Print version

Did you enjoy this article?

(total 0 votes)
Try our own cheap Booking Service72 times read : Adjust font size: Decrease font Enlarge font
image

BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl (NASDAQ: CELG - News ) today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in ...

Read this article...



Post your comment comment Comments (0 posted)

copyright